Topical MK-7 in skin cells and a split-face/neck trial: mitochondrial and anti-aging effects
In the abstract, MK-7 improved mitochondrial readouts in stressed human skin cells and, in a randomized split-face/neck trial of 30 women, improved wrinkles, elasticity and sagging versus placebo over 8 weeks. [1]
Automatic summary · not editorially reviewed
The key findings
In the abstract, MK-7 improved mitochondrial readouts in human skin cells exposed to UVA or hydrogen peroxide. [1]
The human study was a randomized, double-blind, split-face/neck, vehicle-controlled trial with 30 women aged 35–60 who completed 8 weeks. [1]
The abstract reports significant improvements versus placebo in wrinkle roughness, elasticity and sagging over 8 weeks. [1]
The source at a glance
- Study type / format
- Abstract of in vitro cell experiments plus a randomized, double-blind, split-face/neck, vehicle-controlled trial
- Population / context
- Human skin cells under induced oxidative stress in vitro; women aged 35–60 years in the split-face/neck trial (30 completers).
- Summary based on
- Study abstract
- Original publication
- August 14, 2026
MK-7 tested in stressed skin cells
The abstract describes in vitro work in which human skin cells were exposed to UVA or hydrogen peroxide to model oxidative stress, then treated with MK-7. Measured readouts included ATP content, the NAD/NADH ratio, mitochondrial membrane potential, mitochondrial DNA copy number, respiratory chain complex activities and senescence-associated secretory markers. According to the abstract, MK-7 increased ATP production, raised the NAD/NADH ratio, restored membrane potential, preserved mitochondrial DNA copy number under oxidative challenge, enhanced several respiratory complex activities and reduced UVA-induced senescence marker expression. These are cell-level biomarker results, not evidence of human lifespan benefit.
Supporting source [1]
Split-face/neck trial: wrinkles, elasticity, sagging
The human part was a randomized, double-blind, split-face/neck, vehicle-controlled trial. It enrolled women aged 35–60 years, with 30 completers. Each participant applied a 0.05% MK-7 face-and-neck cream to one randomized side and placebo to the other side twice daily for 8 weeks. Wrinkles/roughness, elasticity and sagging were measured with instruments at baseline and at weeks 2, 4 and 8. The abstract reports significant improvements versus placebo in wrinkle roughness on face and neck, improved elasticity parameters and attenuated sagging over 8 weeks. Because each woman served as her own comparison, the contrast is MK-7 cream versus placebo cream on the opposite side.
Supporting source [1]
What the abstract does and does not show
The abstract links improved mitochondrial bioenergetic readouts in vitro with measurable anti-aging effects in the split-face/neck study and supports further development of mitochondrial targeting for skin aging. It does not report how the in vitro findings connect mechanistically to the clinical outcomes, nor long-term effects beyond 8 weeks. The results are associations from a small completed sample of 30 women; they do not establish that MK-7 prevents aging or extends lifespan. Only the abstract was reviewed; the full text was not reviewed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Cell results are biomarkers, not human lifespan evidence; the trial had 30 completers and 8 weeks of follow-up, and associations do not prove causation.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Huang H, Wei R, Xu C, Liu C, Zhao S, Li Y, Wang M. · europepmc.org · August 14, 2026